Trioar

Trioar is a biotech company in Daejeon, South Korea, founded in 2021. It has raised $27.2M across 2 rounds, most recently an $18.0M Series B in July 2025.

Better Ideas. Better Technologies. Better Therapeutics.

Headquarters
Daejeon, Daejeon
Employees
1–10
Founded
2021
Business Model
B2B
Total Funding
$27.2M
Last Round
$18.0M Series BJul 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. The full record is or through the API.

About

TriOar Inc. is a South Korean biotech company developing next-generation antibody-based therapeutics, focusing on antibody-drug conjugates (ADCs) and immuno-oncology (IO) platform technologies designed to improve the therapeutic index by simultaneously reducing toxicity and improving efficacy. The company's proprietary TROCAD platform features a dual-function targeting domain that enhances drug delivery while masking off-target effects, and its TROSIG linker-payload platform provides excellent stability, hydrophilicity, and payload compatibility. Founded in 2021 by seasoned scientists with years of experience in ADC and immunotherapy at Korean biotechs, TriOar is headquartered in Daejeon, South Korea.

Summary

It lists 1–10 employees. It has raised $27.2M in total across 2 rounds, most recently a $18.0M Series B round in Jul 2025. Investors include Woori Venture Partners, Shinhan Venture Investment and Hyundai Technology Investment.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BJul 2025
$18.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Trioar on Indexed.vc
<a href="https://indexed.vc/companies/trioar"><img src="https://indexed.vc/api/badge/company/trioar" alt="Trioar on Indexed.vc" width="260" height="76" /></a>